Life Scientist > Biotechnology

GTG hails successful year despite mixed results

03 September, 2008 by Dylan Bushell-Embling

GTG reports consolidated loss of $5.4 million but representatives still consider the results a win


Anadis clinical trial gets go-ahead

03 September, 2008 by Dylan Bushell-Embling

Anadis obtains Israeli govt approval for mucositis trial protocol


Free access to Elaprase

02 September, 2008 by Dylan Bushell-Embling

Government to fund Genzyme's Elaprase for Hunter syndrome patients


Electronic underpants revealed

02 September, 2008 by Dylan Bushell-Embling

The SimPAD wetness monitoring devices to feature on New Inventors


Dengue vaccine study

02 September, 2008 by Dylan Bushell-Embling

Hawaii Biotech's dengue vaccine program to be supported by Walter Reed


Sonic completes acquisition of GLP

02 September, 2008 by Dylan Bushell-Embling

Medical diagnostics company completes purchase of German medical group


Dung beetles and the sneaky f…er strategy

01 September, 2008 by Graeme O'Neill

Beetles and crickets offer the perfect model for studying sexual selection and the primacy of female choice.


The motherfish and the stunned mullet

27 August, 2008 by Kate McDonald

The recent announcement of “the oldest mother ever discovered” made headlines around the world for Dr John Long and his colleagues, but Materpiscis Attenboroughi is just one of numerous finds Long has made at the Gogo Formation in WA over the last two decades.


Progen gets strategic advice

27 August, 2008 by Dylan Bushell-Embling

Independent advisory firm to help Progen with planning following termination of PI88 study.


NeuroDiscovery has teeth

27 August, 2008 by Dylan Bushell-Embling

NeuroDiscovery demonstrates effectiveness of NSL-101 in dental surgery


Generic partners India pharma

27 August, 2008 by Dylan Bushell-Embling

Indian pharma Lupin invests in Generic Health


Biota records small year-end loss

27 August, 2008 by Dylan Bushell-Embling

Biota’s long-running legal battle with GSK has taken its toll, with the company recording a $20 million loss for the year.


Horses for courses for Bioeffectives

27 August, 2008 by Dylan Bushell-Embling

Bioeffectives show promise as effective treatment of equine gastric ulcers and as a replacement for antibiotics in poultry feed.


No pain for Xenome

21 August, 2008 by Dylan Bushell-Embling

Synthetic venom peptide shows promise in trials


Spine fusion for Mesoblast

21 August, 2008 by Dylan Bushell-Embling

Mesoblast's stem cells effective method for cervical spine fusion


  • All content Copyright © 2025 Westwick-Farrow Pty Ltd